Core Viewpoint - The announcement highlights the successful market entry and first commercial procedure of the Iberis RDN system in Switzerland, marking a significant milestone for the company and its strategic partner [1] Group 1: Product Development and Approval - The Iberis RDN system, developed by Shanghai Antong Medical Technology Co., Ltd., has completed market access and the first commercial surgery in Switzerland [1] - The system is the only renal denervation (RDN) product globally approved for both transradial access (TRA) and transfemoral access (TFA) methods, enhancing safety, efficacy, and cost-effectiveness [1] - The company aims to provide outpatient RDN surgeries for patients worldwide [1] Group 2: Strategic Partnerships - Antong has formed a strategic partnership with Bosheng International Group, covering multiple regions including EU countries, Asia-Pacific, and Latin America (LATAM) for the commercialization of the Iberis RDN system [1] - The collaboration is expected to support the broader distribution and adoption of the Iberis RDN system in various international markets [1] Group 3: Safety and Efficacy - The first commercial procedure at Basel University Hospital reported no complications or adverse events, indicating a positive initial outcome for the Iberis RDN system [1] - The TRA method utilized in the procedure is noted to make RDN safer and more effective compared to traditional methods [1]
百心安-B：IBERIS RDN系统在瑞士完成市场准入及首例商业化手术